ALK

Universal Cellular Machinery · Phosphorylation & Kinase Signaling Cascades

Does an ALK gene finding mean an ALK inhibitor is suitable?

ALK makes a receptor kinase that relays signals from the cell surface. A targeted cancer treatment depends on a relevant tumor alteration and clinical diagnosis, not simply an ALK entry in consumer DNA data.

Common Gene Name
ALK receptor tyrosine kinase
NCBI Gene ID
238
Chromosome
2

Clinical Evidence Status

Actionability report availableEstablished disease relationshipTumor or drug-label biomarker context

These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.

Answer Sources

Explore supporting evidence (22 records)
Condition or drugEvidenceGrade / statusContextSource
neuroblastoma, susceptibility to, 3ClinGen gene-disease validityDefinitiveAutosomal dominantView source
2022-12-30
NeuroblastomaMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2011-03
Lung cancerMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2011-03
Susceptibility to neuroblastoma-3ClinGen clinical actionabilityScored report; not a validity gradePediatricView source
2024-11-21
AlectinibFDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Atezolizumab (4)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Brentuximab Vedotin (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
BrigatinibFDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Cemiplimab-rwlc (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
CeritinibFDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Crizotinib (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Durvalumab (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Ipilimumab (4)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Lorlatinib (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Nivolumab (5)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Pembrolizumab (5)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Pemetrexed (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Tepotinib (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Tremelimumab-actl (1)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
EnsartinibFDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Ramucirumab (3)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Dabrafenib (4)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source

Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.

← Back to Universal Cellular Machinery